Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with CF-FUra.

L R Laufman1, W D Brenckman, K A Stydnicki

  • 1Columbus CCOP, OH 43215.

Advances in Experimental Medicine and Biology
|January 1, 1988
PubMed
Summary

Two trials investigated the efficacy of combination chemotherapy with leucovorin (CF) and fluorouracil (FUra) for metastatic colorectal cancer. Objective responses and disease stabilization correlated with improved survival, demonstrating the treatment

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From the Journals.

Journal of wound care·2016
Same author

Reviews.

Journal of wound care·2016
Same author

Reviews.

Journal of wound care·2016
Same author

Reviews.

Journal of wound care·2016
Same author

Identification of trail pheromone of the antTetramorium caespitum L. (Hymenoptera: Myrmicinae).

Journal of chemical ecology·2013
Same author

Contents of dufour glands of workers of three species of Tetramorium (Hymenoptera: Formicidae).

Journal of chemical ecology·2013

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Background:

  • Metastatic colorectal cancer (mCRC) remains a significant health challenge.
  • Optimizing chemotherapy regimens like leucovorin (CF) and fluorouracil (FUra) is crucial for improving patient outcomes.
  • Minimizing toxicity while maximizing efficacy is a key goal in mCRC treatment.

Purpose of the Study:

  • To evaluate the toxicity and efficacy of two different administration schedules of CF-FUra in patients with mCRC.
  • To assess the correlation between objective responses, disease stabilization, and patient survival.
  • To determine the optimal dosing strategy for oral CF with IV FUra in a pre-randomized trial setting.

Main Methods:

  • Two clinical trials were conducted using CF-FUra in mCRC patients.

Related Experiment Videos

  • Trial 1: IV CF with a constant dose of IV FUra (400 mg/m2).
  • Trial 2: Oral CF with escalating doses of IV FUra, including folate level monitoring.

    • Main Results:

    • Trial 1 showed objective responses in 36% and disease stabilization in 31%, correlating with prolonged survival (median 8-10 months).
    • Toxicity in Trial 1 (diarrhea, weakness) was manageable by dose adjustment.
    • Trial 2 reported a 35% response rate and 35% stabilization, with a median survival of 14 months and 12-month survival of 56%, despite various toxicities.

    Conclusions:

    • CF-FUra demonstrates objective responses and disease stabilization in mCRC patients, correlating with improved survival.
    • Both IV and oral CF combined with FUra show potential efficacy, with manageable toxicity profiles.
    • Further randomized trials are warranted to confirm the superiority of specific CF-FUra regimens in mCRC treatment.